HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, has scheduled a conference call for Thursday, Nov. 12, 2026, at 4:30 p.m. ET to discuss its financial results for the third quarter ended Sept. 30, 2026. The call will also feature updates on recent achievements, including results from the ALIGN-ACS pilot study, and upcoming milestones for the company’s Heart Attack Detection program, according to HeartBeam (NASDAQ: BEAT).
The timing of the call is significant for investors and the medical community because it will provide the first comprehensive look at how HeartBeam’s portable 3D ECG technology is progressing in clinical settings. The ALIGN-ACS pilot study is particularly important as it evaluates the company’s approach to detecting heart attacks outside of traditional hospital environments. Positive results could accelerate the adoption of HeartBeam’s platform, which aims to deliver actionable heart intelligence wherever a patient is located.
Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, Ph.D., and Chief Financial Officer Timothy Cruickshank will host the call, followed by a question-and-answer session. Participants can access the conference by dialing 1-877-704-4453 domestically or 1-201-389-0920 internationally using conference code 13763268. A webcast and accompanying presentation will be available, with a telephone replay accessible approximately three hours after the call through Nov. 26, 2026. A press release detailing the quarterly results will be issued before the call. To view the full press release, visit https://ibn.fm/QEwx4.
HeartBeam’s technology has already achieved key regulatory milestones. The company’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to technology enablement. These clearances position HeartBeam to commercialize a cable-free device that collects ECG signals in three non-coplanar directions and synthesizes them into a 12-lead ECG, potentially redefining cardiac health management by enabling physicians to identify trends and acute conditions without requiring patients to visit a medical facility.
The upcoming earnings call thus represents more than a routine financial update; it is a critical checkpoint for a company attempting to shift the paradigm of cardiac detection. Investors will be listening for details on the ALIGN-ACS data and the path forward for the Heart Attack Detection program. For ongoing updates, the company directs investors to its newsroom at https://ibn.fm/BEAT. Details on the intended use of its technology are available at https://www.heartbeam.com/indications.
The announcement was distributed through MissionIR, a communications platform that is part of the Dynamic Brand Portfolio at IBN. MissionIR provides access to wire solutions via InvestorWire and other services designed to enhance visibility for public companies.
